18 June 2015 | News | By BioSpectrum Bureau
Daiichi Sankyo's subsidiary launches four new generic drugs
Daiichi Sankyo Company Limited has announced that on Friday, June 19, its generics subsidiary, Daiichi Sankyo Espha, will launch seven new generic drugs with four new active ingredients.
The generic drugs to be launched are:
1. Naftopidil OD Tablets 25mg/50mg/75mg DSEP: indicated for the treatment of urination disorder due to enlargement of prostate (Brand: Flivas OD Tablets 25mg, 50mg, 75mg)
2. Metformin Hydrochloride Tablets 250mg/500mg MT: a Biguanide-type oral hypoglycemic agent (Brand: Metgluco Tablets 250mg, 500mg)
3. Letrozole Tablets 2.5mg DSEP: an aromatase inhibitor/postmenopausal breast cancer treatment (Brand: Femara Tablets 2.5mg)
4. Oxaliplatin I.V. Infusion Solution 200mg DSEP; additional strength of formula released in 50mg, 100mg in Dec. 2014: an anti-malignant tumor agent (Brand: Elplat I.V. Infusion Solution 200mg)
Daiichi Sankyo Espha claims that the company has continued to maintain a level of quality based on the quality management standards of the Daiichi Sankyo Group.
The company has undertaken the initiative to launch the world's first double-sided printing on tablets. Daiichi Sankyo Espha has contributed to innovations in formulation and labeling of drugs to make them easier to ingest. These kind of high value-added generic drugs are put forth by Daiichi Sankyo Espha as 'premium generics'.
In order to respond to the risk of patient family members, particularly children, taking their medicine by mistake, a new measure has been introduced for Letrozole Tablets (postmenopausal breast cancer treatment). The new measure is called C-Guard. This PTP sheet was designed so that tablets can only be extracted if an inner sheet if slid up or down to match up with the position of the tablet, thus helping to prevent children taking the drug by mistake.